Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
AuthorsHill-Cawthorne, Grant A.
Tuohy, Orla C.
Jones, Joanne L.
Green, Alison J E
Compston, Alastair D.
Fahey, Michael T.
Coles, Alasdair J.
Permanent link to this recordhttp://hdl.handle.net/10754/561916
MetadataShow full item record
AbstractBackground: Alemtuzumab is a lymphocyte depleting monoclonal antibody that has demonstrated superior efficacy over interferon β-1a for relapsing-remitting multiple sclerosis (MS), and is currently under investigation in phase 3 trials. One unresolved issue is the duration and significance of the lymphopenia induced. The long term effects on lymphocyte reconstitution of a single course, and the consequences that this has on disability, morbidity, mortality and autoimmunity, were examined. Methods: The lymphocyte reconstitution (n=36; 384 person years) and crude safety data (n=37; 447 person years) are reported for the first patients with progressive MS to receive alemtuzumab (1991-1997). Reconstitution time was expressed as a geometric mean or, when a non-negligible number of individuals failed to recover, as a median using survival analysis. Results: Geometric mean recovery time (GMRT) of total lymphocyte counts to the lower limit of the normal range (LLN; ≥1.0×10 9 cells/l) was 12.7 months (95% CI 8.8 to 18.2 months). For B cells, GMRT to LLN (≥0.1×10 9/l) was 7.1 months (95% CI 5.3 to 9.5); median recovery times for CD8 (LLN ≥0.2×10 9 cells/l) and CD4 lymphocytes (LLN ≥0.4×10 9 cells/l) were 20 months and 35 months, respectively. However, CD8 and CD4 counts recovered to baseline levels in only 30% and 21% of patients, respectively. No infective safety concerns arose during 447 person years of follow-up. Conclusions: Lymphocyte counts recovered to LLN after a single course of alemtuzumab in approximately 8 months (B cells) and 3 years (T cell subsets), but usually did not recover to baseline values. However, this long lasting lymphopenia in patients with a previously normal immune system was not associated with an increased risk of serious opportunistic infection.
SponsorsDuring the course of this work, AJC was supported by an MRC Clinical Training Fellowship, Wellcome Intermediate Fellowship and now by the Biomedical Research Centre, Cambridge, NIHR. JLJ is also supported by the Biomedical Research Centre, Cambridge, NIHR. The original studies were supported by a grant from MuSTER.
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.
- Authors: Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K
- Issue date: 2017 Aug 1
- Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
- Authors: Cossburn MD, Harding K, Ingram G, El-Shanawany T, Heaps A, Pickersgill TP, Jolles S, Robertson NP
- Issue date: 2013 Jan 1
- Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
- Authors: Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, Zhu H, Markovic-Plese S
- Issue date: 2013 Dec 15
- Spotlight on alemtuzumab.
- Authors: Jones JL, Coles AJ
- Issue date: 2009 Sep
- Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
- Authors: von Kutzleben S, Pryce G, Giovannoni G, Baker D
- Issue date: 2017 Apr